Two small-molecule Bcl-2 inhibitors, HA14-1 and ABT-737, were found to improve the in vitro cytotoxicity of CTLs and NK cells to the lymphoma and melanoma cells, which might be attributed to sensitizing tumor cells to perforin and granzyme-B with drug treatments [140,141]. This evidence concerns the gene BCL2 and neoplasm.